2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis Inclusion criteria: Patients ≥18 years with symptomatic VTE, 5,395 either DVT proximal to popliteal vein […]
Tag: PE
CANARY Trial Summary: Cath vs AC in PE
2022 CANARY TRIAL Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism parallel, open-label, randomized controlled trial Objective: To assess the effectiveness of catheter-directed thrombolysis (CCDT) compared with anticoagulation among intermediate- to high-risk individuals with acute pulmonary embolism 94 patients Inclusion criteria: Patients ≥18 years with acute pulmonary embolism presenting within 14 days […]
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. Inclusion Criteria: Patients ≥ 18 years with confirmed active cancer within the prior 6 months […]
AXIOMATIC-TKR Trial Summary: Milvexian for the Prevention of VTE
2022 AXIOMATIC-TKR TRIAL Milvexian for the prevention of Venous thromboembolism Parallel-group, Open-label, randomized controlled trial Objective: To compare the efficacy & safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty 1242 patients INCLUSION CRITERIA: Patients undergoing unilateral total knee arthroplasty greater than 50 years of age without contraindicatior to enoxaparin or history of […]